Alterations in Cognitive Function and Cerebral Blood Flow After Conversion From Calcineurin Inhibitors (CNIs) to Everolimus

University of Kansas Medical Center30 enrolled

Overview

The purpose of this study is to learn if changing from Tacrolimus to Everolimus will improve cognitive function by having less effect on brain blood flow.

Study Type

OBSERVATIONAL

Enrollment

Conditions

End Stage Renal Disease

Interventions

TacrolimusDRUG

The patient's physician will prescribe drug according to standard practice.

EverolimusDRUG

The patient's physician will prescribe drug according to standard practice.

Eligibility

Sex: ALLMin age: 18 YearsMax age: 85 Years

Medical Language ↔ Plain English

Inclusion Criteria: * English speaking * able to sign informed consent * able to arrange transportation to and from study site * without acute stroke, concussion or traumatic brain injury * without acute medical issues at the time of participation * At least 12 weeks post Kidney transplant surgery Exclusion Criteria: * are claustrophobic or have other contra-indication for magnetic resonance imaging (MRI) * have hearing or visual impairment * are unable to read, write, speak or understand English * have uncontrolled psychosis or seizure disorder or are currently using antipsychotics or anti-epileptics * taking Envarsus at the time of recruitment

Locations (1)

University of Kansas Medical Center

Kansas City, Kansas, United States

Outcomes

Primary Outcomes

Change in cognitive function

Time frame: Change from Baseline to Week 12

Secondary Outcomes

Change in cerebral blood flow

Time frame: Change from Baseline to Week 12

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.